drugset / Trial / NCT00533481

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

NCT00533481 ↗

Phase 2 Completed 497 enrolled Merck Sharp & Dohme LLC
RandomizedFactorialDouble-blindTreatment

Summary

Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.

Timeline

Start
2004-02
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MK0557 Small molecule — —

Indications